Feasibility of a cell kinetic-based adjuvant chemotherapy trial in axillary node-negative breast cancer
| Autor: | Patrizia Serra, Annalisa Volpi, Liliana Marri, Oriana Nanni, Livia Bernardi, Dino Amadori, Stefano Luzi Fedeli, Anna Maria Vecci, Stefania Naldi |
|---|---|
| Předmět: |
Adult
Oncology Cell kinetics Cancer Research medicine.medical_specialty Adjuvant chemotherapy Thymidine labelling medicine.medical_treatment Breast Neoplasms 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans In patient Prospective Studies Prospective cohort study Aged Chemotherapy business.industry General Medicine Middle Aged medicine.disease Node negative Kinetics Treatment Outcome Italy Receptors Estrogen Chemotherapy Adjuvant Lymphatic Metastasis 030220 oncology & carcinogenesis Feasibility Studies Female Receptors Progesterone business Cell Division Thymidine |
| Zdroj: | Scopus-Elsevier Europe PubMed Central |
| Popis: | Aims and background Accumulated information on biologic prognostic indicators and predictors of response to different types of treatment in patients with different tumor characteristics has made it possible to design clinical protocols on biologic bases. Among cell proliferation indices, the thymidine labelling index (TLI) has proved to be an independent and consistent prognostic indicator over time. Moreover, experimental and retrospective analyses of clinical studies have revealed a direct relation between TLI and response to chemotherapy. On the basis of the results, a prospective clinical protocol on axillary node-negative breast cancer was activated in Italy in 1989. Methods Patients with low TLI tumors were treated with local-regional therapy alone, whereas patients with high TLI tumors were randomized to receive local-regional therapy followed or not by adjuvant chemotherapy consisting of 6 cycles of CMF. Results and Conclusions The present paper reports on the feasibility of a prospective clinical protocol based on a subgroup of patients with specific pathologic (node negative) and biologic (rapidly proliferating) breast cancers. However, patient eligibility was only 11%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|